Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004022 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004022 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute.
The verdict
NCT00004022, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery in treating patients who have stage III or stage IV melanoma.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- BIOLOGICAL autologous tumor cell vaccine
- PROCEDURE surgical procedure
- BIOLOGICAL muromonab-CD3
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-06 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004022
The ClinicalTrials.gov registry entry for NCT00004022 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which therapeutic autologous lymphocytes is the first listed.
NCT00004022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004022 about?
NCT00004022 is a clinical study titled "Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery in treating p...
What is the current status of trial NCT00004022?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-06. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00004022?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), surgical procedure (PROCEDURE), muromonab-CD3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004022?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.